Lumibird: Net Income Up by 146%, But Cash Reserves Shrink
In 2025, the European laser specialist recorded a surge in operational results, with EBITDA increasing by 38% and net income jumping by 146%. However, this impressive performance masks a less shiny reality: a massive increase in working capital needs is consuming cash reserves and reducing free cash flow to €13.1M, revealing logistical and commercial tensions behind the numbers.
Impressive Paper Performance
On paper, Lumibird's results are commendable. EBITDA soared by 38% to €45.6M, representing 20.2% of revenue, a margin increase of 4.3 points. Operating income grew even more rapidly, up by 71.7% to €25.7M. Net income exploded by 146% to €14.0M. This trajectory reflects a strategy of operational improvement bearing fruit: the group increased its gross margin by 1.8 points to 63.5%, combined with strict control of operating costs and reduced restructuring expenses. Revenue itself grew more modestly, at €225.6M (+8.9%), meaning profitability growth far outpaced volume growth.
Underlying Cash Flow Concerns
However, these strong operational performances mask a more worrying cash flow mechanism. Cash flow generated from operations reached €29.0M, which seems comfortable. Yet, the working capital requirement exploded by €15.6M, driven by an increase in customer receivables of €11.0M and inventories of €2.9M. This classic phenomenon during periods of rapid growth reveals operational tensions: the group is producing and selling faster than it collects receivables. Ultimately, free cash flow only reached €13.1M, well below the necessary investments. Gross cash reserves contracted to €61.6M, down from €71.1M a year earlier. Meanwhile, net financial debt remains high at €84.6M, although it decreased by €5.3M. Lumibird must now navigate between its growth ambitions and the reality of operational financing needs.
Confidence for 2026
Nevertheless, the group remains confident for 2026. The momentum is driven by two engines: the Photonics division, boosted by Defense and Space (20% growth in 2025) and the acceleration of Medtech (31% growth, particularly in urology and cardiology). The Medical division should benefit from an innovative product portfolio and a strengthened commercial organization. Lumibird anticipates that growth will continue to fuel margins, alongside operational cost control. As a signal to shareholders, the group has introduced a one-time dividend of €0.37 per share. This payout recognizes the quality of the 2025 results, but comes in a context where cash generation remains constrained. The main risk remains the geopolitical consequences of the conflict in the Middle East, whose impact on Defense and Space activities is currently impossible to quantify.
